Compound Evidence File
#EC-2026-0024
Livagen
Filed under Peptides. The bureau holds 128 laboratory returns for this compound from 55 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
55 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 10.0 | 10.0 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 10.0 | 10.0 | 24 Apr 2026 | 23 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 10.0 | 10.0 | 27 Mar 2026 | 8 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 10.0 | 10.0 | 10.0 | 25 Mar 2026 | 8 May 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 5 | 9.9 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 9.9 | 9.9 | 10.0 | 8 May 2026 | 15 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 20 Mar 2026 | 20 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 4 Nov 2025 | 7 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 23 Nov 2025 | 27 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 9.9 | 9.9 | 10.0 | 16 Feb 2026 | 2 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 9.9 | 9.9 | 10.0 | 28 Mar 2026 | 3 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 9.9 | 9.9 | 10.0 | 27 Nov 2025 | 22 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 9.9 | 9.9 | 9.9 | 25 Apr 2026 | 13 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 9.9 | 9.9 | 10.0 | 23 Dec 2025 | 21 May 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 6 Apr 2026 | 6 Jul 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 3 | 8.6 | 7.9 | 9.9 | 24 May 2026 | 24 May 2026 |
| Mai PeptideCASE #VI-2026-0769 | X | 3 | 8.5 | 6.6 | 10.0 | 25 Apr 2025 | 25 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 4 | 8.4 | 7.9 | 8.8 | 23 May 2026 | 23 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 3 | 8.4 | 8.0 | 8.9 | 25 May 2026 | 25 May 2026 |
| LN PeptidesCASE #VI-2026-0781 | X | 2 | 8.1 | 7.8 | 8.3 | 16 Mar 2025 | 19 Jan 2026 |
| Bulk Peptide SupplyCASE #VI-2026-0446 | X | 1 | 7.8 | 7.8 | 7.8 | 7 May 2025 | 7 May 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 5 | 7.7 | 7.0 | 8.8 | 23 May 2026 | 23 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 3 | 7.7 | 6.0 | 9.6 | 23 May 2026 | 23 May 2026 |
| Skye PeptidesCASE #VI-2026-0451 | X | 5 | 7.6 | 6.2 | 8.6 | 14 Jan 2025 | 24 May 2026 |
| Haikou Mingheng BiotechnologyCASE #VI-2026-0126 | X | 1 | 7.6 | 7.6 | 7.6 | 9 Jun 2025 | 9 Jun 2025 |
| Reta-PeptideCASE #VI-2026-0756 | X | 4 | 7.5 | 6.8 | 8.9 | 27 Feb 2025 | 19 Jan 2026 |
| Dankang BioHealthCASE #VI-2026-0775 | X | 1 | 7.2 | 7.2 | 7.2 | 2 Jul 2025 | 2 Jul 2025 |
| Quenna PMQCASE #VI-2026-0415 | X | 1 | 7.1 | 7.1 | 7.1 | 28 Mar 2025 | 28 Mar 2025 |
| BeiBangAnCASE #VI-2026-0899 | X | 3 | 6.8 | 6.0 | 7.3 | 13 Feb 2025 | 24 May 2026 |
| NexaphCASE #VI-2026-0944 | X | 1 | 6.8 | 6.8 | 6.8 | 11 Jun 2025 | 11 Jun 2025 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 6.8 | 6.8 | 6.8 | 27 Feb 2025 | 27 Feb 2025 |
| Peptide-SCASE #VI-2026-0111 | X | 2 | 6.5 | 6.5 | 6.5 | 17 Dec 2024 | 21 May 2026 |
| PeptiLab ResearchCASE #VI-2026-0267 | X | 1 | 6.5 | 6.5 | 6.5 | 13 Jun 2025 | 13 Jun 2025 |
| Modern AminosCASE #VI-2026-0635 | X | 1 | 6.0 | 6.0 | 6.0 | 3 Jul 2025 | 3 Jul 2025 |
| Welon Peptide SolutionsCASE #VI-2026-0478 | X | 1 | 6.0 | 6.0 | 6.0 | 11 Jun 2025 | 11 Jun 2025 |
| Zenith Jove Peptide ZJCASE #VI-2026-0570 | X | 2 | 5.7 | 4.2 | 7.2 | 24 Apr 2025 | 19 Jan 2026 |
| Royal PeptidesCASE #VI-2026-0264 | X | 3 | 5.6 | 3.8 | 7.7 | 2 Jul 2025 | 17 May 2026 |
| Zztai PeptideCASE #VI-2026-0192 | C | 3 | 5.5 | 3.9 | 6.4 | 6 May 2025 | 21 May 2026 |
| Xian Yihang TechnologyCASE #VI-2026-0656 | X | 3 | 5.5 | 3.4 | 7.9 | 17 Dec 2024 | 21 May 2026 |
| YB PeptideCASE #VI-2026-0813 | X | 1 | 5.4 | 5.4 | 5.4 | 28 Mar 2025 | 28 Mar 2025 |
| Qingdao Saber Technology Pharma QSTCASE #VI-2026-0467 | X | 1 | 5.4 | 5.4 | 5.4 | 2 Jul 2025 | 2 Jul 2025 |
| Qingdao Hongshengda TradingCASE #VI-2026-0334 | X | 1 | 5.2 | 5.2 | 5.2 | 2 Jul 2025 | 2 Jul 2025 |
| Shanghai OuDaXin New Material Technology CenterCASE #VI-2026-0498 | X | 1 | 5.0 | 5.0 | 5.0 | 16 Mar 2025 | 16 Mar 2025 |
| Precision Peptide CoCASE #VI-2026-0559 | X | 1 | 4.9 | 4.9 | 4.9 | 13 Jun 2025 | 13 Jun 2025 |
| Prime PeptidesCASE #VI-2026-0696 | X | 1 | 4.8 | 4.8 | 4.8 | 25 Apr 2025 | 25 Apr 2025 |
| Astro PeptidesCASE #VI-2026-0424 | X | 1 | 4.7 | 4.7 | 4.7 | 16 Mar 2025 | 16 Mar 2025 |
| Limitless Life NootropicsCASE #VI-2026-0980 | X | 2 | 4.5 | 3.1 | 6.0 | 7 May 2025 | 21 May 2026 |
| UWA Elite PeptidesCASE #VI-2026-0130 | X | 1 | 4.5 | 4.5 | 4.5 | 13 Jun 2025 | 13 Jun 2025 |
| HybiopeptidesCASE #VI-2026-0305 | X | 1 | 4.2 | 4.2 | 4.2 | 2 Jul 2025 | 2 Jul 2025 |
| Yabang PeptideCASE #VI-2026-0148 | X | 1 | 4.1 | 4.1 | 4.1 | 24 Apr 2025 | 24 Apr 2025 |
| ZZQ PeptidesCASE #VI-2026-0550 | X | 1 | 4.0 | 4.0 | 4.0 | 13 Feb 2025 | 13 Feb 2025 |
| Coastal PeptidesCASE #VI-2026-0958 | X | 2 | 2.7 | 2.1 | 3.2 | 28 Mar 2025 | 21 May 2026 |
| Peptide ArkCASE #VI-2026-0350 | X | 1 | 0.0 | 0.0 | 0.0 | 11 Jun 2025 | 11 Jun 2025 |
| Lejian Biotech PeptideCASE #VI-2026-0746 | X | 1 | 0.0 | 0.0 | 0.0 | 13 Jun 2025 | 13 Jun 2025 |
| Coffee and PeppersCASE #VI-2026-0274 | X | 1 | 0.0 | 0.0 | 0.0 | 2 Jul 2025 | 2 Jul 2025 |
Open any subject to view the batch-level evidence for Livagen alone.